26 related articles for article (PubMed ID: 3856328)
1. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells.
Madden MZ; Ye X; Chi C; Fisher EL; Wolf MM; Needle GA; Bader JE; Patterson AR; Reinfeld BI; Landis MD; Hathaway ES; Muka JE; O'Neil RT; Karijolich J; Philip M; Rathmell JC
J Immunol; 2023 Aug; 211(4):563-575. PubMed ID: 37341499
[TBL] [Abstract][Full Text] [Related]
3. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma.
Recouvreux MV; Grenier SF; Zhang Y; Esparza E; Lambies G; Galapate CM; Maganti S; Duong-Polk K; Bhullar D; Naeem R; Scott DA; Lowy AM; Tiriac H; Commisso C
Nat Cancer; 2024 Jan; 5(1):100-113. PubMed ID: 37814011
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
[TBL] [Abstract][Full Text] [Related]
5. Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
Lemberg KM; Ali ES; Krecmerova M; Aguilar JMH; Alt J; Peters DE; Zhao L; Wu Y; Nuha N; Asara JM; Staedtke V; Pratilas CA; Majer P; Rais R; Ben-Sahra I; Slusher BS
Mol Cancer Ther; 2023 Dec; 22(12):1390-1403. PubMed ID: 37616542
[TBL] [Abstract][Full Text] [Related]
6. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
7. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity.
Catane R; Von Hoff DD; Glaubiger DL; Muggia FM
Cancer Treat Rep; 1979 Jun; 63(6):1033-8. PubMed ID: 380801
[TBL] [Abstract][Full Text] [Related]
8. Glutamine antagonists in chemotherapy.
Livingston RB; Venditti JM; Cooney DA; Carter SK
Adv Pharmacol Chemother; 1970; 8():57-120. PubMed ID: 4400179
[No Abstract] [Full Text] [Related]
9. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
Lyons SD; Sant ME; Christopherson RI
J Biol Chem; 1990 Jul; 265(19):11377-81. PubMed ID: 2358467
[TBL] [Abstract][Full Text] [Related]
10. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.
Willis RC; Seegmiller JE
J Cell Physiol; 1977 Dec; 93(3):375-82. PubMed ID: 22551
[TBL] [Abstract][Full Text] [Related]
11. [Inactivation of microbial glutamin-(asparagin-)ase by azaserine and 6-diazo-5-oxo-L-norleucine].
Lebedeva ZI; Kabanova EA; Berezov TT
Biull Eksp Biol Med; 1985 Dec; 100(12):696-8. PubMed ID: 4074870
[TBL] [Abstract][Full Text] [Related]
12. DNA damage and repair induced by diazoacetyl derivatives of amino acids with different mechanism of cytotoxicity. Correlations with mutagenicity and carcinogenicity.
Brambilla G; Cavanna M; Carlo P; Finollo R; Sciaba L; Parodi S; Bolognesi C
J Cancer Res Clin Oncol; 1979 May; 94(1):7-20. PubMed ID: 468901
[TBL] [Abstract][Full Text] [Related]
13. Mutagenicity of O-diazoacetyl-L-serine (azaserine) and 6-diazo-5-oxo-L- norleucine (DON) in a soybean test system.
Katoh Y; Maekawa M; Sano Y
Mutat Res; 1995 Mar; 342(1-2):37-41. PubMed ID: 7885392
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a mutant Chinese hamster cell line resistant to the glutamine analog 6-diazo-5-oxo-L-norleucine.
Kaufman ER
Somat Cell Mol Genet; 1985 Jan; 11(1):1-10. PubMed ID: 3856328
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
